Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.71 |
| ▸ | MEN1 | O00255 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.60 |
| ▸ | FEN1 | P39748 | 1/20 | 0.60 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 6/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 4/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16213350 | 0.88 | KMT2A (0.67) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL2482431 | 0.88 | KMT2A (0.71) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213402 | 0.87 | KMT2A (0.67) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL19450641 | 0.85 | KMT2A (0.64) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213279 | 0.85 | KMT2A (0.64) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213548 | 0.84 | KMT2A (0.62) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213249 | 0.83 | KMT2A (0.58) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL19757543 | 0.82 | KDM4E (0.60) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213414 | 0.81 | KDM4E (0.59) | KMT2AALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL16213260 | 0.81 | KDM4E (0.59) | KMT2AALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107417616-A | Methods and compositions for treating beta-thalassemia and sickle cell disease | 中央研究院 | 2017-12-01 | — | — | CN | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2017-10-12 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-9662324-B2 | Methods and compositions for treating β-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2017-05-30 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2016-04-21 | — | — | US | disclosed |
| CN-105492428-A | Methods and compositions for treating beta-thalassemia and sickle cell disease | ACADEMIA SINICA | 2016-04-13 | — | — | CN | disclosed |
| WO-2014179567-A2 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | ACADEMIA SINICA (TW) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170290820-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | KMT2A 2095/4885ALDH1A1 921/4885KDM4E 4391/4885 |
| US-20160106728-A1 | METHODS AND COMPOSITIONS FOR TREATING BETA-THALASSEMIA AND SICKLE CELL DISEASE | HBB, HBZ, HBG1 | KMT2A 2095/4885ALDH1A1 921/4885KDM4E 4391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.